ArticleNature and science of sleep2025
The Clinical and Economic Burden of Idiopathic Hypersomnia and Narcolepsy: A United States Claims-Based Analysis.
Article in Nature and science of sleep, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Narcolepsy and Idiopathic Hypersomnia Real-World Treatment Patterns and Changes in Alerting Agent Use After Low-Sodium Oxybate Initiation: A Retrospective Claims Analysis.Neurology and therapy · 2026Article
- Social determinants of health, clinical outcomes, and healthcare resource utilization in participants with and without narcolepsy in theSleep advances : a journal of the Sleep Research Society · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: Idiopathic hypersomnia and narcolepsy are similar but distinct sleep disorders. This study evaluated the clinical and economic burden experienced by individuals with either condition. Patients and Methods: Merative Results: 11,426 individuals with idiopathic hypersomnia and 31,214 with narcolepsy were included. Median ages were 45 and 43 years, respectively; approximately 65% of each cohort was female. Mean numbers of comorbid conditions across all categories were 15.4 (5.4) and 14.6 (5.7), respectively. Ill-defined conditions (95.6%, 94.4%), nervous system diseases (83.8%, 100.0%), and respiratory system diseases (83.6%, 79.1%) were most common broad clinical classification categories. Both cohorts experienced sleep apnea (62.8%, 52.1%), hypertension (45.7%, 42.9%), hyperlipidemia (42.2%, 38.4%), pain (66.4%, 66.0%), and mood disorders (41.9%, 43.3%). Mean all-cause outpatient visits PPPY among those with ≥1 visit were 28.2 (40.1) and 27.4 (40.6) for individuals with idiopathic hypersomnia or narcolepsy, respectively. Mean all-cause medical costs PPPY were $11,134 ($22,674) and $11,591 ($25,956) for individuals with idiopathic hypersomnia or narcolepsy. Conclusion: Individuals with narcolepsy and idiopathic hypersomnia experience comorbid conditions which bear consequences for healthcare systems; these may be considered when evaluating overall health of individuals with either condition.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.